Market research
21J.F Jounce Therapeutics, Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 89M
- P/E ratio
- Not available
- Analyst target
- 14.5
- Dividend yield
- 0.0%
- Beta
- 0.75
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 89M
- P/E ratio
- Not available
- Analyst target
- 14.5
- Dividend yield
- 0.0%
- Beta
- 0.75
About
About Jounce Therapeutics, Inc
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. As of May 3, 2023, Jounce Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Research context
Jounce Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 21J.F discussion.
5 years, 6 months ago
Jounce Therapeutics, Inc is currently in a long term downtrend where the price is trading 32.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.0.
Jounce Therapeutics, Inc's total revenue rose by inf% to $62M since the same quarter in the previous year.
Its net income has increased by 256.5% to $35M since the same quarter in the previous year.
Finally, its free cash flow grew by 311.3% to $39M since the same quarter in the previous year.
Based on the above factors, Jounce Therapeutics, Inc gets an overall score of 4/5.